

Editorial

*Corresponding author

Maria Beatrice Morelli, School of Pharmacy, University of Camerino, Camerino, Italy

Circulating Tumor Cells: One Step Ahead of Precision Medicine

Maria Beatrice Morelli*

School of Pharmacy, University of Camerino, Italy

Editorial

1869 was the year in which Thomas Ashworth identified cells similar to cancer cells in peripheral blood [1]. Since that first observation, the medicine has made steps forward in the last years. Tumor derived cells found in the circulatory or lymphatic system are called circulating tumor cells (CTCs). It is believed that CTCs are disseminated by primary tumors to initiate metastatic growth at distant organ sites [2]. CTCs are therefore considered important indicators of metastatic disease and prognostic biomarkers [3-5]. Together with cell-free nucleic acids and exosomes found in peripheral blood and other body fluids, they fall within the liquid biopsy, a simple, non-invasive and low-cost diagnostic systems that are able to drive medical decisions and implement precision medicine [6].

CTCs are extremely rare in peripheral blood [7]. They do not have well defined morphological aspects [7]. Moreover, they can cluster together or with leukocytes, platelets, endothelial cells or fibroblasts, having thus survival advantage and protection from the immune system and oxidative stress [8-10].

The Cell Search system is the only technique approved by the US Food and Drug Administration for the detection and enumeration of CTCs in metastatic breast, colorectal, and prostate cancers in the clinical setting [11-14]. This method exploits the over expression of the epithelial cell adhesion molecule (EPCAM) present only in epithelial cancer types [7]. However, in this way CTCs originating from mesenchymal tumors or CTCs are undergoing epithelial-mesenchymal transition (EMT), the process that sustains both CTC migration and extravasation towards secondary sites, escape [15]. Therefore, other techniques for exactly detecting CTCs are necessary. At present, several systems based on CTCs properties are available to detect and isolate them from leukocytes [16]. Thanks to large size (up to 20-30 μm), mechanical plasticity, and dielectric mobility properties compared with blood cells [17-20], CTCs can be isolated through membrane filtration, density gradient stratification, dielectric mobility, photoacoustic and microfluidic separation [21-23]. However, these techniques have a low specificity [24]. Other methods exploit a specific protein expression such as cytometric high-throughput imaging, immunomagnetic separation [25] and negative leukocyte depletion [26]. Here too, there are several restrictions: there are no specific antibodies to use. EPCAM, regarded as a biomarker reflecting a risk factor for tumor recurrence [12], cytokeratins (CK8, CK18, CK19) [27] and specific tumor markers [28-30] are also useful for detection and isolation. On the other hand, EPCAM is usually lost during EMT; moreover, CTCs may acquire a stem cell-like phenotype by expressing markers such as CD44, CD133, and aldehyde dehydrogenase, and both proliferative and self-renewal properties favouring metastatization in secondary tissues [31-32].

Now it is clear that for each patient CTCs are characterized by high heterogeneity [33]. Both primary tumors and metastases evolve over time in response to selective pressure of immune system and therapies [33]. This affects CTCs purification and analysis. For this reason, it is necessary to combine differential methods to isolate functionally heterogeneous CTCs.

Methods based on CTCs protein secretion, on migratory properties cultivating them in synthetic substrates, or CTC-derived organoids are emerging [25-34] in order to let CTCs in routine clinical practice. Of course in these models is not considered the contribution of the microenvironment, such as immune system and vascularization.

In a growing number of tumors, the absolute number of CTCs in a 7.5 ml blood sample is significantly associated with prognosis, giving to CTCs a prognostic value [35]. They can also be relevant both for primary diagnosis, for diversify malignant from benign lesions, for patients' therapy response and not only these [35]. Thanks to the ability to analyse their genomic and proteomic profiles, CTCs can provide information on the presence of molecular potential targets for pharmacological actions. Scientists could have information about DNA mutations, epigenetic changes and mRNA expression driving the development of patient-specific treatments [36].

Conclusion

Although methods for enrichment and isolation of viable CTCs have to be improved, characterization of such cells could help in targeting metastatic progression, micrometastasis, and disease relapse answering several important clinical questions.

References

- Ashworth TR. A case of cancer in which cells similar to those in the tumours were seen in the blood after death. *Aust Med J.* 1869; 14: 146-147.
- Pantel K, Speicher M. The biology of circulating tumor cells. *Oncogene.* 2016; 35:1216-1224.
- Alix-Panabières C, Pantel K. Circulating tumor cells: liquid biopsy of cancer. *Clin Chem.* 2013; 59: 110-118.
- Urtshak S, Alpaugh R, Weiner L, Swaby R. Clinical utility of circulating tumor cells: a role for monitoring response to therapy and drug development. *Biomark Med.* 2008; 2: 137-145.
- Gorges TM, Pantel K. Circulating tumor cells as therapy-related biomarkers in cancer patients. *Cancer Immunol. Immunother.* 2013; 62: 931-939.
- Crowley E, Di Nicolantonio F, Loupakis F and Bardelli A. Liquid biopsy: monitoring cancer- genetics in the blood. *Nat Rev Clin Oncol.* 2013; 10: 472-484.
- Parkinson DR, Dracopoli N, Petty BG, Compton C, Cristofanilli M, Deisseroth A, et al. Considerations in the development of circulating tumor cell technology for clinical use. *J Transl Med.* 2012; 10: 138.
- Krebs MG, Metcalf RL, Carter L, Brady G, Blackhall FH, Dive C. Molecular analysis of circulating tumour cells-biology and biomarkers. *Nat Rev Clin Oncol.* 2014; 11: 129-144.
- Labelle M, Begum S and Hynes RO. Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. *Cancer Cell.* 2011; 20: 576-590.
- Le Gal K, Ibrahim MX, Wiel C, Sayin VI, Akula MK, Karlsson C, et al. Antioxidants can increase melanoma metastasis in mice. *Sci Transl Med.* 2015; 7: 308re8.
- Riethdorf S, Fritsche H, Müller V, Rau T, Schindlbeck C, Rack B, et al. Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the Cell Search system. *Clin Cancer Res.* 2007; 13: 920-928.
- Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. *N Engl J Med.* 2004; 351: 781-791.
- Cohen SJ, Alpaugh RK, Gross S, O'hara SM, Smirnov DA, Terstappen LW, et al. Isolation and characterization of circulating tumor cells in patients with metastatic colorectal cancer. *Clin Colorectal Cancer.* 2006; 6: 125-132.
- Okegawa T, Nutahara K, Higashihara E. Prognostic significance of circulating tumor cells in patients with hormone refractory prostate cancer. *J Urol.* 2009; 181: 1091-1097.
- Satelli A, Mitra A, Brownlee Z, Xia X, Bellister S, Overman MJ, et al. Epithelial-mesenchymal transitioned circulating tumor cells capture for detecting tumor progression. *Clin Cancer Res.* 2015; 21: 899-906.
- van der Toom EE, Verdore JE, Gorin MA, Pienta KJ. Technical challenges in the isolation and analysis of circulating tumor cells. *Oncotarget.* 2016; 7: 62754-62766.
- Gascoyne PR, Shim S. Isolation of circulating tumor cells by dielectrophoresis. *Cancers.* 2014; 6: 545-579.
- Sollier E, Go DE, Che J, Gossett DR, O'Byrne S, Weaver WM, et al. Size-selective collection of circulating tumor cells using Vortex technology. *Lab Chip.* 2014; 14: 63-77.
- Au SH, Storey BD, Moore JC, Tang Q, Chen YL, Javadi S, et al. Clusters of circulating tumor cells traverse capillary-sized vessels. *Proc Natl Acad Sci U S A.* 2016; 113: 4947-4952.
- Park ES, Jin C, Guo Q, Ang RR, Duffy SP, Matthews K, et al. Continuous flow deformability-based separation of circulating tumor cells using microfluidic ratchets. *Small.* 2016; 12: 1909-1919.
- Zheng S, Lin HK, Lu B, Williams A, Datar R, Cote RJ, et al. 3D microfilter device for viable circulating tumor cell (CTC) enrichment from blood. *Biomed Microdevices.* 2011; 13: 203-213.
- López-Riquelme N, Minguela A, Villar-Permy F, Ciprian D, Castillejo A, Álvarez-López MR, et al. Imaging cytometry for counting circulating tumor cells: comparative analysis of the CellSearch vs ImageStream systems. *APMIS.* 2013; 121: 1139-1143.
- Li P, Mao Z, Peng Z, Zhou L, Chen Y, Huang PH, et al. Acoustic separation of circulating tumor cells. *Proc Natl Acad Sci U S A.* 2015; 112: 4970-4975.
- Arya SK, Lim B, Rahman AR. Enrichment, detection and clinical significance of circulating tumor cells. *Lab Chip.* 2013; 13: 1995-2027.
- Alix-Panabieres C, Pantel K. Clinical applications of circulating tumor cells and circulating tumor DNA as liquid biopsy. *Cancer Discov.* 2016; 6: 479-491.
- Palmirotta R, Lovero D, Silvestri E, Felici C, Quaresmini D, Cafforio P, et al. Next-generation Sequencing (NGS) analysis on single Circulating Tumor Cells (CTCs) with no need of Whole-genome Amplification (WGA). *Cancer Genomics Proteomics.* 2017; 14: 173-179.
- Schneck H, Gierke B, Uppenkamp F, Behrens B, Niederacher D, Stoecklein NH, et al. EpCAM-independent enrichment of circulating tumor cells in metastatic breast cancer. *PLoS One.* 2015; 10: e0144535.
- Messaritakis I, Stolidis D, Kotsakis A, Dermizaki EK, Koinis F, Lagoudaki E, et al. TTF-1- and/or CD56-positive circulating tumor cells in patients with small cell lung cancer (SCLC). *Sci Rep.* 2017; 7: 45351.
- Lu SH, Tsai WS, Chang YH, Chou TY, Pang ST, Lin PH, et al. Identifying cancer origin using circulating tumor cells. *Cancer Biol Ther.* 2016; 17: 430-438.
- Beije N, Onstenk W, Kraan J, Sieuwerts AM, Hamberg P, Dirix LY, et al. Prognostic impact of HER2 and ER status of circulating tumor cells in metastatic breast cancer patients with a HER2-negative primary tumor. *Neoplasia.* 2016; 18: 647-653.

31. Correnti M, Raggi C. Stem-like plasticity and heterogeneity of circulating tumor cells: current status and prospect challenges in liver cancer. *Oncotarget*. 2017; 8: 7094-7115.
32. Aktas B, Tewes M, Fehm T, Hauch S, Kimmig R, Kasimir-Bauer S. Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients. *Breast Cancer Res*. 2009; 11: R46.
33. Caswell DR, Swanton C. The role of tumour heterogeneity and clonal cooperativity in metastasis, immune evasion and clinical outcome. *BMC Med*. 2017; 15: 133.
34. Praharaj PP, Bhutia SK, Nagrath S, Bitting RL, Deep G. Circulating tumor cell-derived organoids: Current challenges and promises in medical research and precision medicine. *Biochim Biophys Acta Rev Cancer*. 2018; 1869: 117-127.
35. Palmirotta R, Lovero D, Cafforio P, Felici C, Mannavola F, Pellè E, et al. Liquid biopsy of cancer: a multimodal diagnostic tool in clinical oncology. *Ther Adv Med Oncol*. 2018; 10: 1758835918794630.
36. Mastoraki S, Strati A, Tzanikou E, Chimonidou M, Politaki E, Voutsina A, et al. ESR1 Methylation: A liquid biopsy-based epigenetic assay for the follow-up of patients with metastatic breast cancer receiving endocrine treatment. *Clin Cancer Res*. 2018; 24: 1500-1510.